| 000 | 01614cam a2200301 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030817.0 | ||
| 008 | 130402s2010 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.34.M.Sc.2010.Sa.S | ||
| 100 | 0 | _aSalwa Mosad Mahmoud Soliman | |
| 245 | 1 | 0 |
_aSynthesis, analysis and evaluation of New carbamate derivatives for enhanced brain delivery of baclofen / _cSalwa Mosad Mahmoud Soliman ; Supervised Hilde Spahn Langguth , Khaled AbouZid , Raimund Niess |
| 246 | 1 | 5 | _aتشييد و تحليل و تقييم مشتقات جديدة من كاربامات الباكلوفين لتحسين توصيل عقار الباكلوفين إلى المخ |
| 260 |
_aCairo : _bSalwa Mosad Mahmoud Soliman , _c2010 |
||
| 300 |
_a142 P. : _bcharts ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceutical Chemistry | ||
| 520 | _aThe crntrally acting antispastic agent bactofen )R/S-4 amino-3-(4-chtorophenyl)butyric acid), was experienced to exhibit high therapeutic activity in certain severe spastic disorders. However, therapeutic levels are not reached in the central nervous system (CNS), unless the drug is administered intrathecally | ||
| 700 | 0 |
_aHilde Spahn Langguth , _eSupervisor |
|
| 700 | 0 |
_aKhaled Abouzid , _eSupervisor |
|
| 700 | 0 |
_aRaimund Niess , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c42403 _d42403 |
||